Results 31 to 40 of about 6,731 (217)

How safe is eptifibatide during urgent carotid artery stenting?

Frontiers in Neurology, 2013
Background: Glycoprotein IIB/IIIA inhibitors are occasionally utilized during carotid artery stenting (CAS) in the presence or absence of a visualized intra-operative thrombus. Objective: We assess the hemorrhagic and clinical outcomes associated with
Hesham eAllam, Nirav eVora, Randall eEdgell, Richard Charles Callison, Yasir eAl Khalili, Michelle eStorkan, Amer eAlshekhlee, Amer eAlshekhlee   +7 more
doaj   +1 more source

Platelet glycoprotein IIb/IIIa receptor blockade in coronary artery disease [PDF]

, 2001
Glycoprotein IIb/IIIa inhibitors represent a new promising class of antiplatelet medications. Their use in acute coronary syndromes and for patients undergoing percutaneous coronary intervention has been the subject of a number of large controlled trials
Salam Amar M, Suwaidi Jassim
core   +2 more sources

Association of Ebtifibatide Administration Timing and TIMI Flow of Infarct Related Artery During Primary PCI

Majalah Kardiologi Indonesia, 2013
Background. Optimal administration timing of Glicoprotein IIb/IIIa inhibitor in STEMI patients undergoing Primary PCI is controversial. Several stud -ies have shown that early administration of eptifibatide, which is given to patients with pain awitan of
Abdul Hakim Alkatiri, Yoga Yuniadi, Dicky A Hanafy, Doni Firman, Sunarya Soerianata   +4 more
doaj   +1 more source

Newer agents in antiplatelet therapy: a review. [PDF]

, 2012
Antiplatelet therapy remains the mainstay in preventing aberrant platelet activation in pathophysiological conditions such as myocardial infarction, ischemia, and stroke.
Holinstat, Michael, Yeung, Jennifer
core   +3 more sources

Antiplatelet agents’-ticagrelol and eptifibatide-safety in experimental colitis in mice

The Turkish Journal of Gastroenterology, 2020
Background/Aims: To evaluate the side effects of two antiplatelet agents - ticagrelor and eptifibatide - in mice with experimentally-induced inflammatory bowel disease. Methods and Material: This study was designed as a controlled, animal, drug safety
Stanko S. Petrovic, Milijana M. Vasiljevska, Slobodan D. Obradovic, Dino K. Tarabar, Radoje B. Doder, Ivana J. Majstorovic, Marijana D. Petrovic, Zvonko M. Magic, Bojana M. Cikota, Nenad J. Perisic, Irina A. Brcerevic, Nebojsa S. Manojlovic, Nemanja K. Rancic   +12 more
doaj   +1 more source

Integrins as therapeutic targets: lessons and opportunities. [PDF]

, 2010
The integrins are a large family of cell adhesion molecules that are essential for the regulation of cell growth and function. The identification of key roles for integrins in a diverse range of diseases, including cancer, infection, thrombosis and ...
A Artoni, A Carter, A Etzioni, A Kato, A Loughman, A McDowall, A Qu, A Robinson, A Salas, AD Ricart, AJ Ablooglu, AL Muranyi, AM Weljie, AR Reynolds, AW Partridge, B Furie, BG Feagan, BG Petrich, BP Feuston, BS Coller, C Delbaldo, C Kummer, C Kummer, C Leonardi, C Lu, C Ng, C Rosano, C Warnke, C Xie, CH Polman, CJ Avraamides, CL Leonardi, CL Tofteng, CS Tan, CS Yoon, D Chua, D Cox, D Cox, D Larkin, D Potin, DA Calderwood, DA Calderwood, DA Chudakova, DA Reardon, Dermot Cox, DJ White, DP Chew, DR Phillips, DS Dodd, DS Harburger, E Bernard, E Havrdova, E Manevich, E Ruoslahti, EO Major, FC Gushiken, FE Fleming, G Weitz-Schmidt, GA Caputo, GM D'Abaco, GPA Rice, H Jin, H Yin, H Zhang, H-J Lee, I Ahrens, J Bennett, J Kallen, J Kalra, J Lim, J Morova, J Takagi, J Takagi, J Tamkun, JA Askari, JA Nemeth, JC O'Shea, JE Frampton, JE Smith-Garvin, JP Ortonne, JP Xiong, JP Xiong, JR Fitzgerald, JR Fitzgerald, JR Morgan, JW Tilley, K Aylward, K Peter, K Peter, K Welzenbach, K Yao, K Yuki, KB Gordon, KB Reddy, KL Graham, KL Graham, KL Schornberg, KL Wegener, KR Legate, KV Vijayan, L Dubertret, L Steinman, L Xudong, LM Kenny, M Brennan, M Champe, M Egbertson, M Kim, M Lebwohl, M Martchenko, M Moser, M Raab, M Rosenthal, M Shimaoka, M Shimaoka, M Shimaoka, M Shimaoka, MA Arnaout, Marian Brennan, MC Joseph, ME Cianfrocca, MG Murphy, MN Younes, MP Bonaca, MP Brennan, MP Crump, N Laurens, Niamh Moran, NS Nicholson, O Vinogradova, O Vinogradova, P Hersey, P Koistinen, PA Calabresi, PC McDonald, PE Hughes, PL Stewart, QY Liu, R Anders, R Axelsson, R Blue, R Curtin, R Evans, R Gonzalez-Amaro, R Pytela, R Silva, R Stragies, R Stupp, RA Rudick, RH Aster, RJ Davenport, RJ Davenport, RM Scarborough, RO Hynes, RP Dassanayake, S Honda, S Honda, S Kim, S Kim, S Li, S Liu, S Moschos, S O'Neill, S Wattanasin, SH Watterson, SJ Hyduk, SJ Monkley, SJ Moschos, SJ Shattil, SM Keating, SM Weis, SR Barthel, SR Targan, T Dileepan, T Kwok, T Weller, T Xiao, TA Kelly, TA Yednock, TC Sroka, TE O'Toole, TE Spencer, TJ MacDonald, TM Brophy, TR Gadek, UP Naik, VA Umans, W Humphrey, W Jia, W Neidhart, W Wang, W Yang, X Sewald, Y Aga, Y Funahashi, Y Gong, Y Li, Y Wang, YF Li, YQ Ma   +199 more
core   +1 more source

A Heterozygous Variant in <i>HABP2</i> Causing Increased Risk of Arterial and Venous Thrombosis in a Young Male: Diagnostic and Therapeutic Challenges. [PDF]

Case Rep Med
Thrombosis is a major clinical issue, affecting venous and arterial circulation, increasing morbidity and mortality. While thrombophilia syndromes are established, new genetic polymorphisms in the hyaluronan binding protein 2 (HABP2) gene are not well understood.
Al-Busaidi S, Al-Maqrashi N, Al-Thihli K, Al Rawahi B, Al Farhan H, Al Alawi AM.   +5 more
europepmc   +2 more sources

A comprehensive evaluation of the activity and selectivity profile of ligands for RGD-binding integrins [PDF]

, 2017
Integrins, a diverse class of heterodimeric cell surface receptors, are key regulators of cell structure and behaviour, affecting cell morphology, proliferation, survival and differentiation.
Cavalcanti-Adam, Elisabetta Ada, Geiger, Benjamin, Kapp, Tobias G., Kessler, Horst, Maltsev, Oleg V., Mas Moruno, Carlos, Neubauer, Stefanie, Notni, Johannes, Rechenmacher, Florian, Reuning, Ute, Spatz, Joachim, Wester, Hans-Jürgen, Zarka, Revital   +12 more
core   +2 more sources

Creatine kinase-MB elevation after percutaneous coronary intervention predicts adverse outcomes in patients with acute coronary syndromes. [PDF]

, 2004
AIM: To study the relationship between outcomes and peak creatine kinase (CK)-MB levels after percutaneous coronary intervention (PCI) in patients with non-ST-segment elevation acute ...
Akkerhuis, K.M. (Martijn), Alexander, J.H.P. (John), Armstrong, P.W. (Paul), Califf, R.M. (Robert), Granger, C.B. (Christopher), Harrington, R.A. (Robert Alex), Kilaru, R. (Rakhi), Lincoff, A.M. (Michael), Mahaffey, K.W. (Kenneth), Moliterno, D.J. (David), Ohman, E.M. (Magnus), Roe, M.T. (Matthew), Simoons, M.L. (Maarten), Tardiff, B.E. (Barbara), Topol, E.J. (Eric), Werf, F.J.J. (Frans) van de   +15 more
core   +10 more sources

Ticagrelor and Eptifibatide Bolus Versus Ticagrelor and Eptifibatide Bolus With 2‐Hour Infusion in High‐Risk Acute Coronary Syndromes Patients Undergoing Early Percutaneous Coronary Intervention

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 2017
BackgroundIn patients with non‐ST‐segment elevation acute coronary syndromes, inhibition of platelet aggregation (IPA) with a potent P2Y12 inhibitor, ticagrelor, was inferior to tirofiban infusion at 2 hours, indicating that glycoprotein IIb/IIIa ...
Moazez J. Marian, Oluseun Alli, Firas Al Solaiman, Brigitta C. Brott, Mark Sasse, Tara Leesar, Sumanth D. Prabhu, Massoud A. Leesar   +7 more
doaj   +1 more source